Frankiewicz Mikolaj, Gawlik-Jakubczak Teresa, Kostro Justyna, Matuszewski Marcin
Department of Urology, Medical University of Gdansk, Gdansk, Poland.
Department of Urology, Medical University of Gdansk, Gdansk, Poland.
Transplant Proc. 2020 Oct;52(8):2436-2439. doi: 10.1016/j.transproceed.2020.01.104. Epub 2020 Apr 14.
Urinary tract infections (UTIs) are the most common infectious complications among kidney recipients. They occur due to the lack of an effective antireflux mechanism in the majority of techniques used during kidney transplantation. Subureteral injection of tissue bulking substance is a feasible alternative to open ureteral reimplantation. This paper, to the best of the authors' knowledge, is the first to evaluate the application of polyacrylate/polyalcohol copolymer (Vantris) as the agent for minimally invasive VUR treatment.
Between January 2018 and February 2019, 7 patients presenting with recurrent UTIs and the diagnosis of VUR (vesico-ureteric reflux) after kidney transplantation were enrolled in the study. Patients qualified for the study underwent cystoscopy and, if possible, minimally invasive, endoscopic subureteral application of 1 mL of polyacrylate/polyalcohol copolymer according to the subureteral transurethral injection (STING) technique.
Endoscopic subureteral injection of tissue bulking substance (polyacrylate/polyalcohol copolymer) was successfully performed in 6 patients. In 1 patient it could not be completed because of an inconvenient location of the neo-orifice. In 4 patients (57%) no reduction of the reflux grade was observed in follow-up imaging. The number of UTIs in the follow-up was significantly reduced in 6 of 7 patients (86%) after polyacrylate/polyalcohol copolymer subureteral injection.
Endoscopic treatment of VUR with polyacrylate/polyalcohol copolymer is an effective and safe method as a first-line treatment for patients with recurrent UTIs after kidney transplantation. To obtain clear conclusions, however, it is necessary to study a larger number of patients with a longer follow-up period after surgery.
尿路感染(UTIs)是肾移植受者中最常见的感染性并发症。在大多数肾移植手术技术中,由于缺乏有效的抗反流机制,导致UTIs的发生。输尿管下注射组织填充剂是开放性输尿管再植术的一种可行替代方法。据作者所知,本文首次评估了聚丙烯酸酯/多元醇共聚物(Vantris)作为微创治疗膀胱输尿管反流(VUR)药物的应用。
2018年1月至2019年2月,7例肾移植后出现复发性UTIs且诊断为VUR(膀胱输尿管反流)的患者纳入本研究。符合研究条件的患者接受了膀胱镜检查,若可能,根据输尿管下经尿道注射(STING)技术,在内镜下向输尿管下微创应用1 mL聚丙烯酸酯/多元醇共聚物。
6例患者成功进行了内镜下输尿管下注射组织填充剂(聚丙烯酸酯/多元醇共聚物)。1例患者因新尿道口位置不便而未能完成注射。4例患者(57%)在随访影像学检查中未观察到反流分级降低。7例患者中有6例(86%)在注射聚丙烯酸酯/多元醇共聚物后,随访期间UTIs的发作次数显著减少。
用聚丙烯酸酯/多元醇共聚物内镜治疗VUR,对于肾移植后复发性UTIs患者作为一线治疗是一种有效且安全的方法。然而,为得出明确结论,有必要研究更多患者,并在术后进行更长时间的随访。